

Assessment of the safety and distribution of NVB302 in healthy volunteers

Submission date 03/08/2011	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 16/08/2011	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 27/04/2016	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Salvatore Febbraro

Contact details
Simbec Research Limited
Merthyr Tydfil
United Kingdom
CF48 4DR

Additional identifiers

Clinical Trials Information System (CTIS)
2011-002703-14

Protocol serial number
NVB302/001

Study information

Scientific Title
A phase I, double-blind, randomised, placebo-controlled, dose escalating study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of NVB302 administered orally to healthy volunteers

Study objectives

To evaluate the safety and tolerability of single and multiple oral ascending doses of NVB302 in healthy male and female subjects

Please note that as of 23/10/2012, the following changes were made to this record:

1. The anticipated start date was updated from 24/08/2011 to 26/10/2011
2. The anticipated end date was updated from 21/12/2011 to 16/03/2012

Ethics approval required

Old ethics approval format

Ethics approval(s)

South East Wales Research Ethics Committee, 25/07/ 2011, ref: 11/WA/0205

Study design

Single and multiple dose, double-blind, randomised, placebo-controlled, single centre dose escalating Phase I study

Primary study design

Interventional

Study type(s)

Screening

Health condition(s) or problem(s) studied

Clostridium difficile infection

Interventions

Part A (Single dose): Up to five cohorts of eight subjects will be randomized to receive one of five single oral doses of NVB302 with a starting dose of 100mg or a single oral dose of Placebo. The dose of NVB302 will be administered in an ascending dose fashion from Cohort 1 to 5. Within each cohort, 6 subjects will receive NVB302 and 2 subjects will receive placebo. Subjects will be followed up for 10 days

Part B (Multiple dose): Up to four cohorts of eight subjects will be randomized to receive either 10 days of once daily oral doses of NVB302 (6 subjects) or 10 days of once daily oral doses of placebo (2 subjects). The dose range to be studied will be selected following review of the results from completed cohorts of Part A. Subjects will be followed up for a further 14 days

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

NVB302

Primary outcome(s)

Safety: Measured by adverse events, vital signs, ECG and routine laboratory assessments.

Key secondary outcome(s)

Pharmacokinetic parameters:

1. Plasma: C_{max}, T_{max}, t_{1/2}, AUC_{0-t} and AUC_∞
2. Urine: A_{eu} (Amount of drug excreted)
3. Faeces: A_{ef} (Amount of drug excreted)

Completion date

16/03/2012

Eligibility**Key inclusion criteria**

1. Healthy male and female subjects, between 18 and 64 years of age (inclusive)
2. Female subjects must be postmenopausal or surgically sterilised
3. Female subject of non-child bearing potential with negative pregnancy test at screening
4. Male subjects must be willing to use an effective method of contraception from day 1 until 3 months afterwards
5. Subject has a healthy gastro-intestinal (GI) tract with no clinically significant history of GI disease (including any disorder likely to influence drug absorption) or bowel surgery

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

64 years

Sex

All

Key exclusion criteria

1. Any relevant abnormality in medical history or on examination, including history of dementia, or other psychiatric, neurological, immunological, respiratory or cardiovascular disorder
2. Presence of Clostridium difficile toxin in faecal sample
3. Participation in a clinical study of an unlicensed drug in the previous 16 weeks, or a marketed drug study within the previous 12 weeks
4. Known allergies, including allergy to drugs with a similar chemical structure or class to NVB302 (Type B lantibiotics) or its constituents

Date of first enrolment

26/10/2011

Date of final enrolment

16/03/2012

Locations

Countries of recruitment

United Kingdom

Wales

Study participating centre**Simbec Research Limited**

Merthyr Tydfil

United Kingdom

CF48 4DR

Sponsor information

Organisation

Novacta Biosystems Limited (UK)

ROR

<https://ror.org/03hyrhe39>

Funder(s)

Funder type

Industry

Funder Name

Novacta Biosystems Limited (UK)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type

[HRA research summary](#)

Details

Date created

Date added

28/06/2023

Peer reviewed?

No

Patient-facing?

No